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Abstract
This present study investigated the temporal effects of type 1 diabetes mellitus (T1DM) on adolescent skeletal muscle
growth, morphology and contractile properties using a 90% partial pancreatecomy (Px) model of the disease. Four week-old
male Sprague-Dawley rats were randomly assigned to Px (n=25) or Sham (n=24) surgery groups and euthanized at 4 or 8
weeks following an in situ assessment of muscle force production. Compared to Shams, Px were hyperglycemic (.15 mM)
and displayed attenuated body mass gains by days 2 and 4, respectively (both P,0.05). Absolute maximal force production
of the gastrocnemius plantaris soleus complex (GPS) was 30% and 50% lower in Px vs. Shams at 4 and 8 weeks, respectively
(P,0.01). GP mass was 35% lower in Px vs Shams at 4 weeks (1.2460.06 g vs. 1.9360.03 g, P,0.05) and 45% lower at 8
weeks (1.5760.12 vs. 2.8060.06, P,0.05). GP fiber area was 15–20% lower in Px vs. Shams at 4 weeks in all fiber types. At 8
weeks, GP type I and II fiber areas were ,25% and 40% less, respectively, in Px vs. Shams (group by fiber type interactions,
P,0.05). Phosphorylation states of 4E-BP1 and S6K1 following leucine gavage increased 2.0- and 3.5-fold, respectively, in
Shams but not in Px. Px rats also had impaired rates of muscle protein synthesis in the basal state and in response to
gavage. Taken together, these data indicate that exposure of growing skeletal muscle to uncontrolled T1DM significantly
impairs muscle growth and function largely as a result of impaired protein synthesis in type II fibers.
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Introduction
Type 1 diabetes mellitus (T1DM) is characterized by complete
or near-complete insulin deficiency resulting from an autoim-
mune-mediated selective destruction of the pancreatic b-cells.
Adults with long-standing and poorly controlled T1DM often
present with a number of disease-related complications including
neuropathy, nephropathy, retinopathy and cardiovascular disease
[1]. While it is possible to have these micro- and macrovascular
complications in youth with T1DM, the incidence is rare [2].
Given that skeletal muscle is the largest organ for glucose disposal,
ensuring the maximal growth and development of muscle may
improve the capacity for blood glucose disposal and thereby
attenuate other diabetic complications, a critical strategy for those
with T1DM. At the very least, maximizing muscle mass would aid
in the functional performance and fitness of those living with the
disease.
For many individuals, T1DM onset occurs in childhood and
there is often a protracted period of time before diagnosis. Even
following the diagnosis of T1DM, glycemic management is
difficult and very often suboptimal in childhood and adolescence
[3]. Unfortunately, T1DM onset in youth coincides with a rapid
growth phase of skeletal muscle and atrophic stimuli placed on the
muscle during this time can lead to a rapid and irreversible
remodeling process, resulting in lifetime of reduced muscle mass
and physical capacity [4,5]. Currently, our understanding of the
effects of T1DM on the skeletal muscle of pediatric populations is
vague though some evidence exists that the skeletal muscle of
young adults with T1DM is compromised (e.g. relative muscle
fiber atrophy, sarcomere destruction) even before evidence of
peripheral neuropathy is observed [6–9].
The purpose of this study was to define the temporal effects of
T1DM on adolescent rodent skeletal muscle growth, morphology
and contractile characteristics in a non-genetic, non-pharmaco-
logical model of disease, the 90% partial pancreatectomy (Px) rat.
For this, we examined two separate time points of diabetes
duration to identify the early and late alterations that occur in
response to the hypoinsulinemic/hyperglycemic state. We hypoth-
esized that Px rats would display impaired skeletal muscle growth
and functional capacity and that these impairments would become
more significant with the duration of hypoinsulinemia/hypergly-
cemia. Furthermore, we hypothesized that lowered rates of protein
synthesis would largely be responsible for the attenuated muscle
growth within growing T1DM rats. The results of this study
support our hypothesis that exposure of young muscle to a T1DM
environment results in impairments in skeletal muscle growth, a
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particularly profound in type II muscle fibers. Our findings also
support the hypothesis that this attenuated growth is mediated in
part by impaired protein synthesis, as activation of the mammalian
target of rapamycin (mTOR) pathway is markedly reduced as
early as 4 weeks after the development of T1DM. These findings
help define the temporal alterations occurring to growing skeletal
muscle in response to T1DM and aid in defining the underlying
mechanisms of impaired muscle mass growth and contractile
function.
Methods
Ethics Statement
All experiments were approved by the York University Animal
Care Committee in accordance with Canadian Council for
Animal Care guidelines (protocol #2007-22).
Animal Characteristics
Young, male Sprague Dawley rats (,age 1 month, 45–55 g)
were purchased from Charles River Laboratories (Montreal, QC,
Canada) and allowed to acclimate for 6 days upon arrival. The
animals (100–120 g) were then randomly assigned to one of four
groups: 4 week Sham pancreatectomy (n=10), 4 week Px (n=14),
8 week Sham (n=14), and 8 week Px (n=11). A group of 8
healthy animals four week old male Sprague Dawley rats (mean
weight =10460.9 g; fed blood glucose 6.0860.23 mM) were also
sacrificed following an overnight fast to serve as a baseline for
growth. The two different time periods of hyperglycemia (i.e. 4-
and 8-weeks) were used to determine the time course of myopathic
changes in this T1DM model. Each time point refers to the time
from surgery to the day of harvest. All animals were housed in
pairs and provided with standard rat chow and water ad libitum.
The animal room was maintained between 22–23uC, 50–60%
humidity and a 12 h/12 h light-dark cycle.
On the seventh day following arrival (day 0), animals underwent
surgery to either remove 90% of the pancreas (Px) or to have a
Sham procedure, as described previously [10]. For this, rats were
anesthetized with 2% inhaled isofluorane and an incision was
made extending from the xyphoid process of the sternum to hip
level. Using cotton tip applicators, the splenic, gastric and
duodenal regions of the pancreas were removed leaving all major
vessels intact to not compromise the surrounding organs. The area
within 2 mm of the common bile duct, extending from the duct to
the first part of the duodenum, was left intact and classified as the
residual pancreas (,10% of the initial pancreatic mass). Sham
animals underwent the same surgical procedure but with no
pancreas removal, only titillation of the pancreas with a cotton tip
applicator. All rats recovered in clean, standard rodent cages in
groups of two. Blood glucose levels were measured via tail nick, 4
times (at 09:00 h) in the first week to monitor critical changes in
blood glucose following surgery. Thereafter, measurements were
taken 2 times a week to follow glycemic levels but minimize animal
handling and stress. On day 27, fasting glycemia (after an 18 hour
fast) was also measured. Body mass was measured three times per
week (09:00 h) with animals in the fed state for the duration of the
protocol. On day 25, fed plasma samples were obtained at 08:00 h
for basal corticosterone (CORT; ImmunoChem double antibody
CORT RIA, ICN Biomedicals Inc., Costa Mesa, CA) and insulin
(90080 Ultra Sensitive Rat Insulin ELISA Kit, Crystal Chem Inc.,
IL) concentrations in the 4 week group only. During the 3
rd and
6
th week, food and water consumption were assessed over a
24 hour period, based on 2 animals per cage.
In Situ Muscle Stimulation
Maximum peak force (Fmax) and fatigability of the gastrocne-
mius plantaris soleus muscle complex (GPS) was determined at 4
and 8 weeks after surgery. Following an overnight fast, animals
were sedated with a ketamine/xylazine cocktail, via intraperito-
neal (IP) injection prior to surgery. The surgical procedure and
muscle stimulation via the sciatic nerve was performed following
adaptation to the original protocol described previously by Burke
et al., 1973 [11]. Briefly, the surgical procedure consisted of
carefully removing the skin around the ankle and leg, followed by
removal of the hamstrings to expose the GPS. The sciatic nerve
was carefully dissected and isolated with surgical thread and cut
1.5 cm from its disappearance into the GPS to prevent retrograde
stimulation. A metal pin was sutured to the Achilles tendon for
attachment to the force transducer, and the trochanters of the
femur were pinned to prevent movement of the leg during
isometric contractions. Blood flow to the muscle was left
undisturbed. The muscles were bathed with saline and wrapped
in plastic wrap to prevent desiccation. Optimal voltage and muscle
length was determined for each animal by generating single twitch
contractions at increasing voltages and muscle lengths until no
increase in single-twitch force production were observed. The
muscle length (L0) and voltage that generated the highest single
twitch amplitude was then used throughout the entire stimulation
protocol. The pulse duration was set to 1 msec for all twitch and
tetanic contractions. The stimulation protocol consisted of a force
frequency curve to determine Fmax, followed by a 2 min
stimulation period to determine fatigue resistance. Fmax was
determined using brief, repeated stimulations at increasing pulse
frequencies until no further increase in force was observed (evident
by either a plateau or drop off in force). The greatest force
achieved for each animal using this protocol was considered the
Fmax. Following a two minute recovery period after Fmax
determination, muscle fatigue rate was determined over a 2
minute period of intermittent contractions, stimulating the muscle
for 3 seconds on and 3 seconds off. Stimulation was given via the
sciatic nerve at a frequency that generated 50% Fmax. Twitch
amplitude, time to peak tension and half-relaxation time were also
determined before the fatigue protocol. Time to peak tension was
defined as the time elapsed from the base to the peak of a single
twitch. Half-relaxation time was defined as the time elapsed from
the peak of a single twitch to the point of the twitch amplitude
returning halfway to baseline. All muscle function data were
collected through an AD Instruments Bridge Amp and Powerlab
4/30, and analyzed with Chart5 PowerLab software (ADInstru-
ments, Inc., Colorado Springs, CO).
Tissue Collection, Blood and Enzyme Activity Analyses
Following the stimulation protocol, animals were euthanized via
decapitation with blood and tissues harvested immediately. Muscles
were extracted, the soleus was removed from the GPS and tissues
were weighed using a standard laboratory bench scale. The length
of the GP was taken using a micrometer. Portions of muscle tissues
from the unstimulated leg were mounted on a 2 cm diameter cork
base using mounting medium and then quick-frozen in liquid
nitrogen-cooled isopentane. Decapitation blood was collected and
plasma was separated and analyzed for fasted non-esterified free
fatty acids (NEFA; HR Series NEFA-HR2 kit; Wako Diagnostics,
Richmond, VA) and insulin (90080 Ultra Sensitive Rat Insulin
ELISA Kit, Crystal Chem Inc., IL) concentrations. Cytochrome c
oxidase (COX) activity of the GP and soleusmuscles weremeasured
from liquid nitrogen snap frozen samples on the contralateral limb
based on previously reported procedures [12].
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To identify skeletal muscle fiber type, a metachromatic myosin
ATPase stain was performed on 10 mm thick cross sections of the
GP muscles using a modified Ogilvie and Feeback protocol [13].
Sections were pre-incubated in an acidic buffer (pH=4.40) to
differentially inhibit myosin ATPases within the different fiber
types. In this protocol using light microscopy, type I fibers appear
dark blue, type IIa appear pink and type IIb and IId are not
discernible from each other and classified as IIb/d. These fibers
appear bluish-purple. The mixed gastrocnemius and plantaris
regions of both the 4 and 8 week group were identified on each
section and a representative image of each muscle region was
acquired for analysis. Over 200 fibers were counted per
microscope image, per animal, to determine fiber type composi-
tion in a given area. Average fiber area was quantified based on
the average area of ,20 fibers for each fiber type per image [14].
Quantification analysis was performed with Adobe Photoshop CS
version 8.0 and reported in mm
2. All images were acquired with a
Nikon Eclipse 90i microscope and Q-Imaging MicroPublisher 3.3
RTV camera with Q-Capture software.
Succinate dehydrogenase (SDH) activity was assessed using a
histochemical analysis and expressed in relative optical density to
Shams, as previously described [14]. The same muscle regions of
the mixed gastrocnemius that were used for fiber typing were used
for SDH activity determination. For this, serial sections were used
to directly compare levels of SDH in each fiber, to each fiber type.
SDH activity is reported as average optical intensity of SDH in
each fiber.
Markers of Mammalian Target of Rapamycin (mTOR)
Signaling, Fractional Protein Synthesis Rates and Protein
Degradation
Eukaryotic initiation factor 4E binding protein 1 (4EBP1) and
p70/p85-S6 protein kinase (S6K1) are key components in the
mRNA translation machinery for protein synthesis. Both 4EBP-1
and S6K1 are downstream phosphorylation targets of the
mammalian target of rapamycin (mTOR) that stimulate mRNA
translation initiation and thus muscle protein synthesis in the post-
absorptive state. To determine if mTOR signaling was impaired in
Px animals in response to feeding, another group of age matched
Px (n=8) and Sham (n=6) rats were administered a leucine
gavage 4 weeks post surgery in the fasted state (18 hours) to mimic
an acute feeding stimulus [15]. For the protein feeding stimulus, a
solution of 20 g of leucine (L-Leucine, cat # L8912, Sigma-
Aldrich Canada, Oakville, ON, Canada) was dissolved in 1L
distilled water. Half of the rats in each group (n=4 and 3 in Px
and Shams, respectively) were administered, via oral gavage,
standardized volumes of the solution (0.48 g of L-Leucine per kg of
body weight) while the other half were administered an equivalent
volume of water (24 mL/kg). This amount of leucine intake is
representative of what is thought to stimulate protein synthesis in
young rats [15]. Thirty minutes following oral gavage, the animals
were killed by decapitation and the gastrocnemius was quickly
removed, separated from the plantaris and flash frozen in liquid
nitrogen for future analysis.
For analysis of 4EBP-1 and S6K1, mixed gastrocnemius muscle
(100 mg) was homogenized on ice in 10 parts buffer (in mM: 20
HEPES, 2 EGTA, 50 NaF, 100 KCl, 0.2 EDTA, 50 glycerolpho-
sphate, pH 7.4) supplemented with 1 mM DTT, 1 mM
benzamidine, 0.5 mM sodium vanadate, protease inhibitor
cocktail and phosphoatase inhibitor 2 cocktail (P8340, P5726;
Sigma-Aldrich Canada, Oakville, ON, Canada) and then
centrifuged 30 minutes at 13,000 RPM and at 4uC [16]. Samples
were quantified for protein concentration using the BioRad
Protein Assay Kit (BioRad, Canada). Acrylamide gels were
prepared by using the Bio-Rad electrophoresis equipment, 15%
for 4EBP-1 and 10% for S6K1 and ubiquitinated proteins. Equal
amounts of protein were loaded into each well. The gels were run
at 120 V for 2 hrs and then transferred onto PVDF membranes at
85 V for 3 hr. Nonspecific sites were blocked by incubation in 5%
BSA in TBS-T and then incubated overnight at 4uC with primary
antibody. For analysis of 4EBP-1, primary antibody (#9644; Cell
Signaling Technologies, New England Biolabs, Pickering, ON,
Canada) was applied in 1:10,000 ratio. For analysis of phosphor-
ylated S6K1 (Thr 389) and total S6K1, primary antibody (#9234,
#9202; Cell Signaling Technologies, New England Biolabs,
Pickering, ON, Canada) was applied in a 1:1,000 ratio.
Protein synthesis was measured in mixed gastrocnemius muscle
samples in 4 week animals using the flooding dose method
developed by Garlick et al. [17]. For this, L-[2,3,4,5,6-3H]
phenylalanine (TRK648, GE Healthcare Canada) was combined
with unlabelled phenylalanine (150 mM in PBS, #5202 EMD
Chemicals Canada) to give a 50 mCi/ml solution of L-[2,3,4,5,6-
3H] phenylalanine to be injected into the animals. The muscle
powder of ,100 mg of tissue was homogenized in 1 mL of cold
2% HClO4 and centrifuged at 2000 g for fifteen minutes. The
supernatant was then collected and ,0.5 mL of saturated
potassium citrate was added. This sample was centrifuged at
2000 g for fifteen minutes and was used to determine the specific
radioactivity of free phenylalanine in the precursor pool. Protein-
bound phenylalanine was obtained by washing the pellet with
4 mL of HClO4 four times and then hydrolyzing the protein in
5 mL of 6 M- HCl for 24 hours at 110uC. HCl was removed via
evaporation using a vacuum system and the amino acids were re-
suspended in 1 mL of 0.5 M sodium citrate. An enzymatic
conversion to b-phenethylamine was then performed to account
for [H3] phenylalanine that may have been converted into [H3]
tyrosine. For this, ,1.25 mL of the supernatant and 0.8 mL of
hyrosolate was incubated with 0.20 mL or 0.285 mL, respectively,
from a 2units/mL L-tyrosine decarboxylase solution (cat #
T7927, Sigma-Aldrich Canada) for 20 hours at 50uC. b-
phenethylamine was extracted by adding 0.5 mL of 3 M NaOH
and 5 mL of chloroform: n-heptane (1:3). Samples were shaken
and centrifuged at 500 g for 5 minutes and the organic layer from
these samples was removed and 2.5 mL of chloroform and 1 mL
of 0.1 M H2SO4 was added. Again samples were shaken and
centrifuged at 500 g for 5 minutes and then the upper aqueous
phase was removed. Subsequently, both the supernatant and the
pellet were assayed for phenethylamine using a modified version of
a method developed by Suzuki and Yagi [18]. For this, 0.1 mL of
2 mM L-leucyl-L-alanine, 0.5 mL of 1 M potassium phosphate
and 0.2 mL of 50 mM ninhydrin were added to specific volumes
of the supernatant and the pellet. Samples were incubated for 30
minutes at 60uC and then cooled in ice for fifteen minutes.
Fluorescence was measured using a 96 well plate reader (Synergy
HT Multi-Mode Microplate Reader, BioTek, USA). Finally,
specific activity was calculated by dividing the radioactivity of each
sample by its concentration of phenethylamine [(DPM/mL)/
(nmol/mL)]. Fractional rates of protein synthesis (ks) were
determined using the formula ks= (SB * 100)/(SA * t), where t
is the time interval between the time of injection and the freezing
of sample in liquid nitrogen expressed in days, SB is the specific
activity in the protein bound amino acids and SA is the specific
activity in the precursor pool.
For degradation analysis, we assessed the ubiquitin proteolytic
system as it is the main intracellular proteolytic pathway in muscle.
Because proteins to be degraded are first ubiquitinated prior to
Adolescent Diabetic Myopathy
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ubiquitinated protein reflects increase in the activity of the
pathway and correlates with increased muscle proteolysis [19].
For this analysis, primary antibody (sc-8017; Santa Cruz
Biotechnology, Santa Cruz, CA) was applied in 1:1,000 ratio.
Secondary antibody (ab6789, ab6721; Abcam Inc., Cambridge,
Massachusetts, U.S.A) was applied in 1:10,000 ratio. Enhanced
chemiluminescent detection (WBKL S05 00; Millipore, Etobicoke,
Ontario, Canada) and Kodak Image Station were used to visualize
the bands. Results are expressed as a fraction of phosphorylated to
total protein. Results for 4EBP-1 are expressed as the fraction of c
(the most phosphorylated) to the total of a, b and c. Phophorylated
S6K1 was expressed relative to total S6K1.
Data analysis
A two-way mixed analysis of variance (ANOVA), followed by a
Fisher post hoc test if necessary, was used for analysis of blood
glucose, body mass, food consumptions and water intake over the
experimental period. Since we had data for both 4- and 8- week
animals for the above parameters over the first four weeks, these
data were pooled for analysis and graphical representation.
ANOVAs were also conducted on force-frequency curves, fatigue
curves, muscle twitch tension, rise time and half relaxation time
and M wave amplitude. Two-way factorial ANOVAs were used
for the analysis of organ/muscle masses, absolute and relative
Fmax, fiber area and muscle SDH activity. Chi squared tests are
performed on muscle mass and fiber area growth between 4 and 8
weeks. For within the same time periods (i.e. 4 or 8 weeks), t-tests
were used for comparisons between Px and Sham rats for the
following variables: GP muscle length, cytochrome c oxidase
activity; and hormone concentrations. Scion Image Software
(Scion, Frederick, MD) was used to measure the optical density of
S6K1 and 4EBP-1 protein expression and a one-way ANOVA was
used for analysis. Statistical analysis was completed using Statistica
6.0 statistical software (StatSoftH, Tulsa, OK), with P#0.05 as the
criterion for statistical significance. All data are expressed as mean
6 standard error of mean (SEM).
Results
Animal Characteristics
Whole blood glucose concentrations and body masses in the fed
state in Px and Sham groups over the 8 weeks of study are shown
in Figure 1. Px rats had elevated blood glucose levels two days
after surgery (P,0.05) and values remained elevated (.25 mM)
throughout the experimental period. On day 28, at the time of
harvest of the 4 week groups, ,18 hour overnight fasted whole
blood glucose concentration was also higher in Px vs. Shams
(measured in gavaged animals only: 8.161.3 mM, n=8 vs.
4.360.2 mM, n=6, P,0.001). Body mass of Px rats was
significantly lower than Shams by day 4 of the protocol and
remained significantly less than Shams throughout the rest of the
experimental period (Figure 1). In the fasted state, Px rats weighed
26% less than Sham-surgery rats at 4 weeks (Sham: 34066 g vs.
Px: 25169, P,0.05) and 33% less by 8 weeks after T1DM
development (Sham: 46668 g vs. Px: 311616 g, P,0.05).
Food and waterintakeat3and6 weekspostsurgeryillustrate that
Pxratswerehyperphagic(3weeks:Sham:6262vs.Px =97612 g/
day, P,0.05; 6 weeks: Sham: 5762 vs. Px: 10564 g/day, P,0.05)
and polydipsic (3 weeks: Sham: 8263 vs. Px: 416629 ml/day,
P,0.05; 6 weeks: Sham: 6867 vs. Px: 452632 ml/day, P,0.05)
compared to Sham surgery rats.
GP, tibialis anterior and soleus masses at 0-, 4- and 8- weeks in
Px and Shams are shown in Table 1. At both 4 and 8 weeks of
T1DM, all muscles measured in Px rats weighed significantly less
than Shams (all P,0.05). Although both Px and Sham animals
had greater muscle masses at 8 weeks when compared to 4 weeks
(both P,0.05), indicating that growth had occurred, the percent
change in GP mass was significantly greater in the Shams than in
the Px animals (Chi square, P,0.05). The percent change in mass
of the soleus and tibialis anterior muscles were not significantly
different between Shams and Px. GP length was similar between
groups at 4 weeks (Sham: 1.2660.08 vs. Px: 1.2360.07 cm;
P.0.05), however, Px muscle length was significantly less than
Shams at 8 weeks (Sham: 3.2660.06 vs. Px: 3.0060.09 cm;
P,0.05). Compared with Shams, Px rats also had severe
reductions in retroperitoneal fat mass at 4 weeks (2.7960.31 g
vs. 0.2260.09 g) and at 8 weeks (5.2760.45 g vs. 0.1960.16 g)
(both P,0.001). Similarly, epididymal fat pad mass was less in Px
than in Shams at 4 weeks (0.6860.08 g vs. 2.6960.33 g) and at 8
weeks (1.0660.14 g vs. 5.2160.29 g) (both P,0.05).
At 4 weeks post-surgery, fasted insulin concentrations were
similar between Px and Shams, while at 8 weeks post-surgery the
Px rats had ,50% less fasted insulin levels than Sham rats
(Table 2). In Px rats, insulin levels failed to increase in response to
feeding, while in Shams, levels increased more than three fold in
response to feeding (Table 2). In the fed state, basal (0800 h)
glucocorticoid concentrations at ,3.5 weeks post-surgery tended
to be elevated in Px compared to Shams, though not significantly
so (P=0.07; Table 2), likely because of the high variance in the Px
Figure 1. Fed blood glucose levels and body masses in Px and Sham rats following surgery. Blood glucose level was higher in Px vs.
Shams on day 2 following surgery and throughout the protocol (P,0.05). Body mass was lower in Px vs. Shams at day 4 following surgery and
throughout the rest of the protocol (P,0.05). Arrows indicate time of harvest for 4 week (n=14 Px; 9 Shams) and 8 week (n=11; 15 Shams) groups.
doi:10.1371/journal.pone.0014032.g001
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compared to Sham surgery rats at both 4 and 8 weeks (P,0.05;
Table 2).
Muscle Function
Figure 2 shows the force frequency curves and fatigue profiles at
4 and 8 weeks in the Px and Sham rats. At 4 weeks, Px rats had
attenuated absolute tetanic contractile force production, particu-
larly at higher stimulation frequencies (i.e. $30 Hz), compared to
Shams (Figure 2, upper left panel). The dynamics of force
production, when expressed relative to Fmax in each group, were
similar between Sham and Px rats (Figure S1). As disease duration
progressed, the Px rats had a reduced tetanic contractile force
production at all stimulation frequencies tested compared to
Shams (Figure 2, upper right panel), although the dynamics of
force production remained similar between groups (Figure S1). In
the Shams, there were increases in absolute force generation at all
stimulation frequencies between 4 and 8 weeks (P,0.05),
indicative of increased strength with maturation, while no gain
in force generation was observed between 4 and 8 weeks in Px rats
(Figure 2).
Absolute maximal tetanic force production (Fmax) at 4 and 8
weeks is shown in Figure 2, middle panel. Fmax in Px rats was
,30% lower than Shams at 4 weeks and ,50% lower at 8 weeks.
Moreover, Fmax increased by ,50% in Shams between 4 and 8
weeks but did not change significantly with time in Px rats (4 week:
Sham: 15.061.62 N vs. Px: 9.9760.81 N; 8 week: Sham:
22.261.74 N vs. Px: 12.361.31 N, group by time interaction,
P,0.05). When expressed relative to the muscle mass of the GPS
(N/g muscle mass), there were no differences in Fmax between
groups nor between time points (4 week Sham =7.8660.91; 4
week Px =7.9560.91; 8 week Sham =6.8360.51; 8 week Px
=6.9460.48 N/g).
Absolute force generation during the two minute fatigue
protocol is shown in Figure 2, lower panels. As expected, the
absolute force production was initially lower in Px than in Shams
at both 4 and 8 weeks, given that the fatigue protocol was designed
to elicit initial contractions of 50% Fmax. At the end of the two
minute fatigue protocol, the level of fatigue observed between
groups was similar. When expressed relative to initial force (see
Figure 2, lower panel insets), Px rats displayed an attenuated force
decline (4 weeks: 6165% reduction in force; 8 weeks: 4763%
reduction in force) compared to that observed in Shams at both 4
and 8 weeks (4 weeks: 7864% reduction in force; 8 weeks: 7266%
reduction in force; p,0.05 both time points).
Muscle twitch rise time is commonly used as a marker of
intracellular calcium release. Muscle compound action potential
(i.e. M wave) is an index of neuromuscular propagation, or the
process involved in converting an axonal action potential into a
muscle fiber action potential. Muscle twitch characteristics and M
wave amplitude in Px and Shams at 4 and 8 weeks are shown in
Table 3. Absolute twitch tension, time to peak tension and half-
relaxation time were all similar between Px and Shams at 4 weeks.
At 8 weeks, time to peak tension and half-relaxation time were less
in Px than in Shams (both P,0.05).
Muscle Fiber Cross-Sectional Area
The cross sectional areas of type I, IIa and IIb/d fiber types of
the mixed gastrocnemius muscles is shown in Figure 3. Significant
group by time interactions existed in all fiber types (all P,0.05).
The type I fiber cross-sectional area was less in Px vs. Shams at
both 4 and 8 weeks (both P,0.05) but both groups had significant
increases in fiber area from 4 to 8 weeks (both P,0.05). Similarly,
type IIa fiber cross-sectional area was less in Px vs. Shams at both
Table 1. Anthropometric data for Px and Sham groups at 4 and 8 weeks.
Tissue 0 Weeks 4 Weeks 8 Weeks
Sham
change
wks 4–8
Px change
wks 4–8
Sham mass (g) Sham mass (g) Px mass (g) Sham mass (g) Px mass (g)
Gastrocnemius-plantaris 0.5160.01 1.9360.03
# 1.2460.06
#,* 2.8060.06 w 1.5760.12 *w 146% 127% d
Tibialis anterior 0.1760.01 0.6160.01
# 0.4060.02
#,* 0.8260.02 w 0.4860.03 *w 139% 121%
Soleus 0.0460.001 0.14860.011
# 0.09860.004
#,* 0.19660.006 w 0.12460.008 *w 135% 127%
Epididymal fat 0.3160.03 2.6960.33
# 0.6860.08
#,* 5.2160.29 w 1.0660.14 * 165% 157% d
Retroperitoneal fat 0.2660.02 2.7960.31
# 0.2260.09
#,* 5.2760.45 w 0.1960.16 * 189% 89% d
Note:
# indicates 4 week significantly greater than baseline at P,0.05.
*indicates that Px is significantly less than Sham for the same time point at P,0.05.
w indicates that 8 week values are significantly higher than at 4 weeks within the same group at p,0.05.
d indicates a significant change in growth between 4 and 8 weeks.
doi:10.1371/journal.pone.0014032.t001
Table 2. Fed and fasted plasma hormone concentrations at 4
and 8 weeks.
Week Sham Px
Basal fasted insulin
concentration (ng/ml)
4 0.5460.08 0.4760.08
8 0.8060.10 0.4260.04*
Basal fed insulin
concentration (ng/ml)
4 5.7960.59 0.8060.20*
Basal fed glucocorticoid
concentration (ng/ml)
4 19.363.03 69.3622.8
Fasted non-esterified fatty
acids (mM)
4 0.4460.07 0.2260.04*
8 0.3960.03 0.2860.25*
T-tests were performed on plasma hormone concentrations.
*indicates that Px is significantly less than Sham for the same time point at
p,0.05. Basal glucocorticoid levels tended to be higher in Px than Shams
(P=0.07).
doi:10.1371/journal.pone.0014032.t002
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PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e14032Figure 2. In situ muscle stimulation force frequency curves (A), Fmax (B) and fatigue index curves (C) at 4 and 8 weeks in Px and
Sham rats. At 4 weeks, Px rats displayed lower contractile force compared to shams at frequencies $30 Hz (upper left panel). At 8 weeks, Px showed
less force generation at all stimulation frequencies (upper right panel). Maximal tetanic force (Fmax) was lower in Px compared to Sham rats at both 4
and 8 weeks (center panel) and only increased with time in the Shams (#,P ,0.05). Absolute contractile force during the 2 minute fatigue protocol
was less at the start of the test in Px compared to Shams at both 4 and 8 weeks (bottom left and right panels), but values reached similar fatigue
endpoints by the end of 2 minutes. When expressed as a percentage of initial force (insets), Px had a smaller decline in force over time at both 4 and 8
weeks. * indicates Px different from Sham at p,0.05; # indicates greater than 4 weeks (P,0.05).
doi:10.1371/journal.pone.0014032.g002
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grow with time in both groups (both, P,0.05). Finally, type IIb/d
fiber areas were lower in Px than Shams at both 4 and 8 weeks
(both P,0.05) and only grew significantly in the Shams (P,0.05).
The findings of reduced cross sectional areas in all fiber types in
the mixed gastrocnemius muscles and severely attenuated growth
of the type IIb/d fibers in Px rats was consistent with measures
made in the plantaris muscles (data not shown).
Oxidative Enzyme Activity
Muscle oxidative markers (COX and SDH activity) were
measured at the 8 week time point and were consistently lower
in diabetic rat muscle. Specifically, COX activity in the GP was
lower in Px (6.7260.49 mmole/min/g) than in Shams
(10.661.1 mmole/min/g) (P,0.05). SDH activity, as measured
by histological staining in the mixed gastrocnemius, was also
significantly lower in Px compared to Shams in all fiber types
(Sham vs. Px, respectively-type I; 181612 vs. 152616; type IIa;
20669.4 vs. 183615; type IIb/d 174611 vs. 152613% Relative
Optical Density). This finding was consistent with measures made
in the plantaris muscle (data not shown).
mTOR Signaling, Fractional Rates of Protien Synthesis
and Protein Ubiquitination
As mentioned above, at 4 weeks post surgery, another group of
Sham (n=6) and Px (n=8) rats were fasted for ,18 hours and
subjected to either oral gavage of L-leucine or distilled water. The
animals were then killed 30 minutes later for the determination of
key markers of protein synthesis and ubiquitination. 4EBP-1 and
S6K1 phosphorylation in mixed gastrocnemius muscle increased
2-fold and 3.5-fold, respectively, following leucine gavage in
Shams and was unchanged in Px rats (both P,0.05, Figures 4A
and 4B).
In another subset of identically treated animals (n=8 Shams; 6
Px), fractional protein synthesis rates, expressed as a percentage of
amino acid incorporation into muscle protein per day, were
measured 4 weeks post surgery by injection of [3H]phenylalanine
tracer either with or without leucine gavage. Protein synthesis rates
were significantly lower in Px than in Shams (main effect of group
P,0.05) and only increased with leucine gavage in the Shams
(Figure 4C, P,0.05). Finally, ubiquitinated protein levels, when
measured in the fasted state, were similar between groups and
were unchanged by leucine feeding (Figure 4D).
Discussion
In this study, we show that muscle growth and contractile force
production are profoundly impaired in the Px rodent model of
adolescent T1DM and that this impairment is likely as a result of
reduced rates of muscle protein synthesis. Specifically, we found
that the skeletal muscle growth of all fiber types (type I, IIa, IIb/d),
and overall force production of the gastrocnemious/plantaris
complex, are dramatically attenuated at 4 and 8 weeks after the
onset of hypoinsulinemia/hyperglycemia in growing Px rats
compared with Sham-surgery rats. Furthermore, our results
indicate that indices of protein synthesis (i.e. mTOR signaling
and fractional rates of protein synthesis) are dramatically reduced
in growing T1DM muscle with no observable differences in
protein degradation, at least when measured in the fasted state (as
assessed by global protein ubiquitination in fasted and leucine fed
animals). The profound changes in young skeletal muscle exposed
to the negative environment of uncontrolled T1DM suggests that
early detection and intervention is of critical importance in
pediatric populations to ensure that optimal muscle growth is not
jeopardized, thereby affecting the potential for muscle mass
accumulation and long-term physical capacities.
Long-standing, poorly controlled T1DM results in a number of
disease-related complications including neuropathy, nephropathy,
retinopathy and cardiovascular disease [1]. Another complication
of T1DM is muscle weakness and reduced skeletal muscle mass, a
complication that may be termed clinically as a ‘‘myopathy’’,
although some debate exists if this term is appropriate as skeletal
muscle force production per unit of mass (or cross sectional area)
may not necessarily be impaired in persons with T1DM [20].
Table 3. Muscle twitch characteristics at 4 and 8 weeks.
Week Sham Px
Absolute twitch tension (N) 4 6.1260.62 5.6460.93
8 6.6860.99 5.2360.98
Time to peak tension (ms) 4 30.363.55 31.362.49
8 36.862.78 29.560.97*
Half- relaxation time (ms) 4 32.166.93 35.265.84
8 40.367.69 24.061.74*
Note:
*indicates that Px is significantly less than Sham for the same time point at
p,0.05.
doi:10.1371/journal.pone.0014032.t003
Figure 3. Muscle fiber areas in mixed gastrocnemius at baseline (time 0) and at 4 and 8 weeks in Px and Shams. In all fiber types, there
were main effects for group, main effects for time, and group by time interactions (all P,0.05). & indicates significantly greater than week 4 (P,0.05).
* indicates Px lower than Shams (P,0.05).
doi:10.1371/journal.pone.0014032.g003
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long-standing disease who have clinically detectible peripheral
neuropathy [21–24], evidence also exists that children and young
adults with short-term T1DM exhibit reduced physical capacities
[25–30], impaired growth velocities [31,32] and abnormalities in
their GH–IGF-I axis [33], even when anthropometrically- and/or
activity-matched. These findings suggest that a lower muscle
volume may exist in young people with T1DM well before other
micro- and macrovascular complications arise.
What remains to be fully elucidated are the effects of untreated
or poorly controlled T1DM on adolescent skeletal muscle growth,
function and phenotype, at a time when muscle growth rates
normally would peak. The rate of whole body protein degradation
and amino acid oxidation are enhanced in adolescents with
Figure 4. Phosphorylation of 4E-binding protein 1 (4E-BP1) (A) and S6K1 (threonine 389) (B) with, or without, leucine gavage,
fractional protein synthesis rates (C) and total ubiquinated proteins (D) in gastrocnemius muscle of Sham and Px rats. Muscles were
harvested 30 minutes following a gavage in the fasted state of either leucine (+) or water (2) at 4 weeks post surgery (for further details, see
methods). On phosphorylation, 4E-BP1 migrates with different mobilities (i.e. a,b,c, the c-form being the most phosphorylated.) Data are expressed as
the fraction of 4E-BP1 in the c-form to the total of all 4E-BP1 forms, expressed as a percentage of Sham rats with water gavage. S6K1 (threonine 389)
phosphorylation is also expressed as percentage of Shams with water gavage. Fractional protein synthesis rates, expressed as a percentage per
24 hours, was lower in Px than in Shams (main effect of group, P,0.05) and increased in response to leucine gavage in Shams but not in Px animals.
Total ubiquitinated proteins, normalized to a-tubulin, in gastrocnemius muscle 30 minutes following either water or leucine gavage are expressed
relative to Shams. Ubiquitinated protein levels did not change significantly with leucine gavage and so the data were pooled into Sham and Px
groups for statistical analysis. * P,0.05 vs Sham (2).
doi:10.1371/journal.pone.0014032.g004
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therapy has been shown to reduce rates of protein degradation but
not increase rates of protein synthesis in adolescents with the
disease [35]. To date, however, few studies have investigated the
effects of adolescent T1DM on skeletal muscle and contractile
performance in T1DM, although some rodent data suggests that
muscle protein synthesis rates may be impaired in insulin deficient
animals (for a review see [36] and [20]). In a recent study, we
compared the diabetic myopathy in the Ins2
Akita+/2 murine model
of T1DM with the commonly used streptozotocin model and
found several important differences in muscle characteristics [14].
However, we did not examine muscle growth in that study per se,a s
only one time point was assessed (8 weeks following diabetes
induction) and no measures of protein synthesis were performed.
While earlier studies attempted to define the mechanisms that
contribute to impaired structure and function of skeletal muscle
with T1DM, streptozotocin (STZ) administration was the
diabetogenic agent was frequently used to induce hypoinsulin-
emia/hyperglycemia [37–45]. The use of the STZ model for the
investigation of T1DM myopathy may lead to incorrect
conclusions, however, as STZ, a potent DNA methylating agent,
has been shown to have direct effects on skeletal muscle
independent of hyperglycemia/hypoinsulinemia [46].
The effects of T1DM on overall growth in humans are well
documented [47], as is the physiological effects of insulin on
muscle growth [36]. There is a blunted pubertal growth spurt as
evidenced by reduced peak height velocity standard deviation
scores in insulin treated boys and girls with T1DM [48–51]. The
effects on muscle growth, per se, in adolescents with the disease
have yet to be fully clarified. In this study, we observed dramatic
attenuation in overall growth, as measured by total body mass,
muscle mass, fat mass and skeletal muscle length, between 4 week
old and 13 week old Px rats, which corresponds to the adolescent
period in rats. That these rodents are still in the growth phase of
development is particularly evident in Sham operated rats given
the large increases in body mass, muscle masses and fiber areas
throughout the experimental protocol (Figures 1 and 3, Table 1).
Although growth was impaired in all fiber types of the Px
animals in this study, we found that type II fibers, particularly the
IIb/d form, were considerably more susceptible to attenuations in
growth rate (Figure 3). In fact, we failed to measure any significant
increase in type IIb/d fiber area between 4 and 8 weeks in the Px
animals, while these same fibers nearly doubled in size in the
Shams. These observations are consistent with reports of smaller
type II fiber areas and muscle mass in other models of T1DM
[14,38,52]. Together, these data suggest that the diabetic
environment, at least under the conditions of this study (i.e. severe
hyperglycemia/hypoinsulinemia and sedentary behavior) has
greater deleterious effects on type II compared with type I fibers.
By looking at this early time course of disease progression, we have
extended these previous observations of reduced muscle mass size
and have shown that the impairment in muscle growth in type II
fibers with this disease is likely most dramatic during adolescence.
Specifically, during pre adolescence (i.e. time 0 in this study, age 4
weeks in rats), all muscle fibers are of similar size and the relative
reductions in fiber area growth between pre adolescents to
adolescents (from 0 to 4 weeks) in the Px rats are consistent across
fiber types (Figure 3). However, during later stages of adolescence,
it has been reported that type I fibers do not increase dramatically
in size, while type II fibers, particularly the type IIb/d fibers,
undergo significant hypertrophy [53]. Our findings clearly indicate
that if muscle is exposed to the T1DM environment during the
critical stages of adolescence, a dramatic impairment in type II
fiber growth will occur.
An alternative explanation exists for the more profound affect of
T1DM on type IIb/d fiber growth in the conditions of this study
(i.e. sedentary cage conditions). It is important to note that
sedentary cage living in rodents likely recruits primarily the type I
and IIa muscle fibers and not type IIb/d fibers. Moreover, it is well
established that mechanical loading (i.e. exercise) overcomes the
requirement of insulin to increase muscle mass in all muscle fiber
types [54]. Thus, conceivably, it may be that the attenuation in
growth of the type IIb/d fibers in the Px rats is largely because
these rats were primarily sedentary in nature and not using these
fast twitch muscle fibers on a regular basis. This finding may be
clinically important as it suggests that newly diagnosed T1DM
adolescents are at increased risk for impaired muscle growth and
development, particularly if they are sedentary. Importantly,
reduced type IIb fiber mass accumulation has been implicated in
the deterioration of insulin sensitivity and body composition in
rodents [55], both of which would place the diabetic individual at
a further disadvantage from a glycemic management point of view.
Whether or not the impairment in muscle growth can be
normalized by intensive insulin therapy or by increased physical
activity or a combination of these treatments requires urgent
investigation.
The mechanisms for impaired muscle growth in T1DM are not
entirely clear. The reduced insulin concentrations in T1DM would
be expected to directly impair muscular protein synthesis in
response to feeding and could be the major contributing factor to
the phenotype observed in human and animal models of the
disease [56]. As expected, we observed considerably lower fed
plasma insulin levels in Px rats; levels that mimic that of prolonged
fasting in Sham animals (Table 2) and muscle protein synthesis
rates in the Px rats were about 50% of that observed in Shams
after leucine feeding (Figure 4C). Protein feeding, and the resultant
rise in circulating insulin levels in healthy individuals, is thought to
be important in limiting protein breakdown and maintaining
muscle mass during growth and development in humans with
T1DM [57] and is directly involved in activating protein synthesis
through the mTOR signaling pathway. Both 4E-BP1 and S6K1
are downstream phosphorylation targets of mTOR and stimulate
mRNA translation initiation in the post-absorptive state. The
initiation phase of mRNA translation plays a pivotal role in the
regulation of protein synthesis [58]. We found that following
leucine gavage, which simulates protein feeding in rats, there was
virtually no increase in phosphorylation status of these key
synthesis markers in the Px rats (Figures 4A and 4B). This finding
is in line with the observation that insulin plays an important role
in the activation of mTOR signaling following amino acid intake
in muscle [59]. Taken together, our results provide strong
evidence that the attenuation in muscle growth in Px rats was
related to a down regulation of the mTOR signaling cascade and
reduced rates of protein synthesis in response to nutrient feeding.
However, it is important to note that some muscle protein
synthesis did still occur during adolescence in this animal model of
T1DM, as evidenced by the increase in muscle mass, fiber areas
and fractional rates of protein synthesis, perhaps independent of
insulin signaling and 4E-BP1 or S6K1 phosphorylation, as has
been suggested previously [59]. Our observations that despite
hyperphagia, circulating insulin levels remain in a fasted state in
Px rats are also in support of the hypothesis that insulin deficiency
in this model explains much of the attenuation in body mass gain
and muscle mass growth. Nevertheless, other disturbances in
metabolism, such as elevations in glucocorticoids (Table 2),
increases in interleukin-6 levels or reductions in insulin-like growth
factor-1 may also play a role in attenuating muscle growth in
T1DM [20].
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types, likely accounts for the lower absolute force production
observed at 4 weeks of diabetes. Indeed, when expressed per unit
of muscle mass, Fmax was similar between Px and Sham animals
both at 4 weeks and 8 weeks. However, with continued exposure
to the T1DM environment, the attenuated growth of type II fibers
in the Px animals likely accounts for the inability of their muscles
to generate any increase in absolute maximal force production
between the 4 and 8 week time period. In comparison, the muscles
from Sham rats displayed a 50% increase in maximal tetanic
force production from 4 to 8 weeks, likely as a result of their
dramatic increase in their type II fiber cross sectional area. A
recent investigation into the muscle contractile characteristics of
Ins2
Akita+/2 mice revealed similar reductions in maximal force
capacity relative to control mice [14]. Consistent with this prior
work, we found that relative peak force production was normal in
T1DM rats as were the contractile dynamics when expressed
relative to Fmax, indicating that attenuated muscle growth is the
primary contributor to reduced force production, and not a
specific effect of T1DM on the myofibrillar apparatus. Taken
together, these observations help to explain the documented
decrease in skeletal muscle performance in young people with
T1DM when compared to their age-matched peers [60,61].
Somewhat surprisingly, we observed reductions in muscle twitch
time to peak tension and half-relaxation time at 8 weeks, but not at
4 weeks, in Px vs. Sham rats (Table 3). This apparent increase in
twitch performance would normally indicate an increase in fast
myosin properties (i.e. type IIb/d fibers), which is indeed counter
to what we have speculated to have occurred in these animals. It
may be that the small reduction in peak twitch amplitude at 8
weeks might explain the reduced contraction and relaxation time
in these animals, although an increase in the number of type II
fibers (although with reduced fiber areas) with T1DM, as has been
observed in human studies of T1DM [62,63], can not be ruled out.
Consistent with studies using STZ rodents that report
reductions in oxidative capacity [62,64,65], we also found
reductions in SDH and COX activity in the GP muscles in the
8 week Px group. Despite these reductions in oxidative enzymes,
we observed attenuation in relative muscular fatigue rates at both
4 and 8 weeks after Px- compared to Sham- surgery (Figure 2
inset). However, when the 8 week fatigue protocol traces are
viewed in absolute terms (Figure 2), a dramatic reduction in force
generation is initially observed in the Sham-surgery rats compared
with Px. We would speculate that fatigue of the larger mass of IIb/
d (fast glycolytic) fibers in the Sham group, relative to Px,
accounted for this precipitous drop and therefore, when made
relative to initial force would be viewed as a fatigue-resistance in
Px animals. While this hypothesis requires confirmation, support
comes from our previous work in Ins2
Akita+/2 mice that showed no
difference in relative fatigue rates between control and 8 week
diabetic mice when a low-frequency fatigue protocol (2 min; 2 Hz)
was utilized [14]. The low-frequency fatigue protocol in that
previous study would have likely been of insufficient magnitude to
elicit fatigue in type II fibers.
Our Px model of T1DM clearly has some limitations that
should be discussed. While it may be speculated that removal of
acinar cells belonging to the exocrine portion of the pancreas
could account for reductions in body/tissue mass accumulation, it
has been reported previously that following 90% pancreatectomy
the digestive function of the pancreas is well maintained [66–68].
Moreover, the reduction in body mass observed in our Px animals
is consistent with the ,20% reduction in mass observed in
hyperglycemic Ins2
Akita+/2 mice [14]. We also found that direct
leucine gavage (which would not require digestive enzymes for
intestinal absorption) resulted in an impaired response in mTOR
signaling in Px rats, which suggests that a relative reduction in
digestive enzymes had a minimal effect on the impaired muscle
growth in these animals. Finally, as pointed out in the above
discussion, the observations made in this study may only pertain to
young Px rats who are not treated with exogenous insulin or
allowed physical activity, unlike what is typically done in the
clinical care of young patients with T1DM. As such, the relevance
that this study has to humans with T1DM remains to be
established.
In summary, we found that adolescent T1DM skeletal muscle is
severely impaired in its capacity for growth, particularly if this
occurs at a time when type II fiber development is taking place.
The impaired growth can account for the impairments in force
production, as force generation made relative to muscle mass was
not different between groups. Unlike the other micro- and
macrovascular complications associated with long standing
diabetes, these differences in muscle growth and resultant
decrements in contractile performance exist early on in the
disease process. Our data point to impairments in protein
synthesis, at a time when these pathways would normally be
accelerated. Given that optimal growth is a major goal in the
intensive treatment of T1DM children, these results should aid in
defining new therapeutic strategies to ensure proper skeletal
muscle growth and maximize skeletal muscle mass into adulthood.
Supporting Information
Figure S1 Force frequency curves in Px and Sham groups at 4
and 8 weeks, expressed relative to Sham Fmax values (upper
panels) and to the Fmax values in each group (lower panels).
Found at: doi:10.1371/journal.pone.0014032.s001 (0.48 MB TIF)
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